HLA’s future impact on allogeneic cell therapy development

From cell bank creation to maximizing population coverage

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

6 Considerations When Evaluating Cell Sourcing Vendors

Including questions to ask potential cell sourcing partners

Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

5 Qualities to Seek in Your Cell Therapy Supply Chain Vendor

Considerations to help lower your cell or gene therapy logistics risk

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

The role of ‘super donors’ in cell therapy scalability

Why reliance on a small subset of donors could introduce risk for companies